BIOATLA INC. news, videos and press releases
For more news please use our advanced search feature.
BIOATLA INC. - More news...
BIOATLA INC. - More news...
- BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
- BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
- BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
- BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
- BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
- BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
- BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
- BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
- BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
- BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
- BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
- BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
- BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
- BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
- BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
- BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
- BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
- BioAtla to Participate in the Jefferies Global Healthcare Conference
- BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
- BioAtla to Participate in the Citizens JMP Life Sciences Conference
- BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
- BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
- BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
- BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
- BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
